This study has demonstrated that BCKDK localizes to breast cancer cell nuclei, where it binds to and phosphorylates RNF8, thereby blocking ubiquitin‐mediated degradation of RAD51 and enhancing HRR. Here, BCKDK is linked to breast cancer.